Peter S. Talbot

Peter S. Talbot

Auto-generated profile, based on publicly available information

Peter S. Talbot

Division of Neuroscience and Experimental Psychology, Faculty of Biology, Medicine and Health, The University of Manchester , Manchester

Research Focus & Metrics

Academic Career Length

28Years (1999-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 November 2005 in Biological Psychiatry
Verified
Journal Article
Closed access
DMDiana Martinez
Diana Martinez
RGRoberto Gil
Roberto Gil
MSMark Slifstein
Mark Slifstein
DHDah-Ren Hwang
Dah-Ren Hwang
YHYiyun Huang
Yiyun Huang
AAAnissa Abi-Dargham
Anissa Abi-Dargham

1 January 2018 in Biological Psychiatry
Verified
Journal Article
Open access
SHSophie E. Holmes
Sophie E. Holmes
RHRainer Hinz
Rainer Hinz
SCSilke Conen
Silke Conen
CGCatherine J. Gregory
Catherine J. Gregory
JMJulian C. Matthews
Julian C. Matthews
PTPeter S. Talbot
Peter S. Talbot
Major depressive disorder is associated with raised peripheral inflammatory markers. Mounting evidence also suggests that inflammation is involved in suicidal behavior. However, the involvement of inflammation in the brains of individuals with depression, and its association with suicidal ideation, needs further clarification. Translocator protein (TSPO), which is upregulated in activated glia (predominantly microglia), can be measured as an indication of neuroinflammation in vivo using positron emission tomography and TSPO-specific radioligands. We used [11C](R)-PK11195 positron emission tomography to compare TSPO availability in the anterior cingulate cortex (ACC), prefrontal cortex, and insula between 14 medication-free patients in a major depressive episode of at least moderate severity and 13 matched healthy control subjects. In a post hoc analysis, we also compared TSPO availability between patients with and without suicidal thoughts. Multivariate analysis of variance indicated significantly higher TSPO in patients compared with control subjects (p = .005). The elevation was of large effect size and significant in the ACC (p = .022, Cohen's d = 0.95), with smaller nonsignificant elevations in the prefrontal cortex (p = .342, Cohen's d = 0.38) and insula (p = .466, Cohen's d = 0.29). TSPO was not elevated in patients without suicidal thinking but was significantly increased in those with suicidal thoughts compared with those without, most robustly in the ACC (p = .008) and insula (p = .023). We confirm evidence for increased TSPO availability, suggestive of predominantly microglial activation, in the ACC during a moderate to severe major depressive episode. Our findings provide further incentive for evaluating anti-inflammatory therapies in major depressive disorder.

12 December 2019 in Journal of Psychopharmacology
Verified
Journal Article
Closed access
PDF file
TBThomas Re Barnes
Thomas Re Barnes
RDRichard Drake
Richard Drake
CPCarol Paton
Carol Paton
SCStephen J Cooper
Stephen J Cooper
BDBill Deakin
Bill Deakin
AYAlison R Yung
Alison R Yung
These updated guidelines from the British Association for Psychopharmacology replace the original version published in 2011. They address the scope and targets of pharmacological treatment for schizophrenia. A consensus meeting was held in 2017, involving experts in schizophrenia and its treatment. They were asked to review key areas and consider the strength of the evidence on the risk-benefit balance of pharmacological interventions and the clinical implications, with an emphasis on meta-analyses, systematic reviews and randomised controlled trials where available, plus updates on current clinical practice. The guidelines cover the pharmacological management and treatment of schizophrenia across the various stages of the illness, including first-episode, relapse prevention, and illness that has proved refractory to standard treatment. It is hoped that the practice recommendations presented will support clinical decision making for practitioners, serve as a source of information for patients and carers, and inform quality improvement.

1 May 2005 in American Journal of Psychiatry
Verified
Journal Article
Closed access
PDF file
WFW. Gordon Frankle
W. Gordon Frankle
ILIlise Lombardo
Ilise Lombardo
ANAntonia S. New
Antonia S. New
MGMarianne Goodman
Marianne Goodman
PTPeter S. Talbot
Peter S. Talbot
LSLarry J. Siever
Larry J. Siever

16 October 2018 in Therapeutic Advances in Psychopharmacology
Verified
Journal Article
Open access
PDF file
IJIbrahim Jawad
Ibrahim Jawad
SWStuart Watson
Stuart Watson
PHPeter M. Haddad
Peter M. Haddad
PTPeter S. Talbot
Peter S. Talbot
RMR. Hamish McAllister-Williams
R. Hamish McAllister-Williams
A number of effective maintenance medication options exist for bipolar disorder (BD) and these are regarded as the foundation of long-term treatment in BD. However, nonadherence to medication is common in BD. For example, a large data base study in the United States of America (USA) showed that approximately half of patients with BD were nonadherent with lithium and maintenance medications over a 12 month period. Such nonadherence carries a high risk of relapse due to the recurrent nature of the illness and the fact that abrupt cessation of treatment, particularly lithium, may cause rebound depression and mania. Indeed, medication nonadherence in BD is associated with significantly increased risks of relapse, recurrence, hospitalization and suicide attempts and a decreased likelihood of achieving remission and recovery, as well as with higher overall treatment costs. Factors associated with nonadherence include adverse effects of medication, complex medication regimens, negative patient attitudes to medication, poor insight, rapid-cycling BD, comorbid substance misuse and a poor therapeutic alliance. Clinicians should routinely enquire about nonadherence in a nonjudgmental fashion. Potential steps to improve adherence include simple pragmatic strategies related to prescribing including shared decision-making, psychoeducation with a clear focus on adherence, reminders (traditional and digital), potentially using a depot rather than an oral antipsychotic, managing comorbid substance misuse and improving therapeutic alliance. Financial incentives have been shown to improve adherence to depot antipsychotics, but this approach raises ethical issues and its long-term effectiveness is unknown. Often a combination of approaches will be required. The strategies that are adopted need to be patient specific, reflecting that nonadherence has no single cause, and chosen by the patient and clinician working together.

1 December 2005 in American Journal of Psychiatry
Verified
Journal Article
Closed access
RNRajesh Narendran
Rajesh Narendran
WFW. Gordon Frankle
W. Gordon Frankle
RKRichard Keefe
Richard Keefe
RGRoberto Gil
Roberto Gil
DMDiana Martinez
Diana Martinez
AAAnissa Abi-Dargham
Anissa Abi-Dargham